https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7607 Wed 11 Apr 2018 15:15:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16769 Wed 11 Apr 2018 09:29:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40943 Wed 10 May 2023 10:32:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38927  5 years post-diagnosis). Analysis was undertaken for the 6-month supervised exercise portion of the intervention, which involved 100 men aged between 62 and 85 years, 50 in each arm. The primary outcome was cost per quality-adjusted life-years (QALYs). Results: A 6-month supervised exercise intervention for PCa survivors resulted in an incremental cost-effectiveness ratio of AU$64,235 (2018 AUD) at an incremental cost of AU$546 per person and a QALY gain of 0.0085. At a willingness-to-pay of AU$50,000, the probability that the intervention is cost-effective was 41%. Sensitivity analysis showed that maintenance of benefits via a 6-month home-based intervention, immediately following the supervised intervention, lowered the cost per QALY gained to AU$32,051. Discussion: This is the first cost-effectiveness analysis of exercise for PCa survivors. The intervention was effective, but unlikely to be cost-effective at the generally accepted willingness-to-pay of AU$50,000 per QALY. It is likely that evidence to support cost savings from post-intervention outcomes would reveal greater benefits and contribute to a more comprehensive cost-effectiveness analysis. Future RCTs should incorporate longer follow-up durations and collection of data to support modelling to capture future health benefits. Measures of quality of life or utility more sensitive to the impact of physical activity would also improve future economic evaluations.]]> Tue 08 Mar 2022 11:43:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41392 Tue 02 Aug 2022 17:47:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44701 Thu 20 Oct 2022 15:58:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17463 5 yr postdiagnosis on physical functioning.Design, setting, and participants. Between 2010 and 2011, 100 long-term PCa survivors from Trans-Tasman Radiation Oncology Group 03.04 Randomised Androgen Deprivation and Radiotherapy previously treated with androgen-deprivation therapy and radiation therapy were randomly assigned to 6 mo of supervised exercise followed by 6 mo of a home-based maintenance programme (n = 50) or printed educational material about physical activity (n = 50) for 12 mo across 13 university-affiliated exercise clinics in Australia and New Zealand. Intervention: Supervised resistance and aerobic exercise or printed educational material about physical activity. Outcome measurements and statistical analysis: The primary end point was a 400-m walk as a measure of cardiovascular fitness. Secondary end points were physical function, patient-reported outcomes, muscle strength, body composition, and biomarkers. Analysis of covariance was used to compare outcomes for groups at 6 and 12 mo adjusted for baseline values. Results and limitations: Participants undergoing supervised exercise showed improvement in cardiorespiratory fitness performance at 6 mo (−19 s [p = 0.029]) and 12 mo (−13 s [p = 0.028]) and better lower-body physical function across the 12-mo period (p < 0.01). Supervised exercise also improved self-reported physical functioning at 6 (p = .006) and 12 mo (p = 0.002), appendicular skeletal muscle at 6 mo (p = 0.019), and objective measures of muscle strength at 6 and 12 mo (p < 0.050). Limitations included the restricted number of participants undertaking body composition assessment, no blinding to group assignment for physical functioning measures, and inclusion of well-functioning individuals. Conclusions: Supervised exercise training in long-term PCa survivors is more effective than physical activity educational material for increasing cardiorespiratory fitness, physical function, muscle strength, and self-reported physical functioning at 6 mo. Importantly, these benefits were maintained in the long term with a home-based programme with follow-up at 12 mo. Clinical trial registry: The effect of an exercise intervention on cardiovascular and metabolic risk factors in prostate cancer patients from the RADAR study, ACTRN: ACTRN12609000729224.]]> Sat 24 Mar 2018 08:04:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20738 Sat 24 Mar 2018 08:00:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20479 Sat 24 Mar 2018 07:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17874 Sat 24 Mar 2018 07:56:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21252 3 months (chronic). Results: Of these men, 85% were able to meet the criteria for the attainment of V·O_2max, whereas three positive tests (3.2%) were observed. The three participants who recorded a positive stress test underwent further medical examination and were subsequently cleared of clinically significant cardiovascular disease. Apart from the relatively low V·O_2max (24.7 ± 6.0 mL·kg⁻¹·min⁻¹, 10th–15th percentile), compared with normative data in healthy age-matched controls, the cardiovascular response to exercise was similar in this cancer population. Moreover, treatment duration did not seem to influence cardiovascular responses to exercise. This early evidence suggests that risk of adverse events during maximal exercise testing is relatively low in this population and certainly no higher than that in ages-matched, apparently healthy individuals. Conclusions: Maximal exercise testing was demonstrated to be feasible and safe, providing a direct assessment of V·O_2max. The relatively low number of positive tests in this study suggests that the risk of adverse events is relatively low in this population and certainly no higher than that in age-matched, apparently healthy individuals.]]> Sat 24 Mar 2018 07:54:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18526 Sat 24 Mar 2018 07:50:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28140 Sat 24 Mar 2018 07:36:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28842 Sat 24 Mar 2018 07:33:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26742 Sat 24 Mar 2018 07:24:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42994 Fri 09 Sep 2022 14:03:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54664 28.4 kg/m2 , performing supervised resistance or unsupervised mixed exercise (19.8% dropout) or had low-medium education and performed aerobic or supervised mixed exercise (13.5%). The lowest dropout was found for participants with BMI >28.4 kg/m2 and high education performing aerobic or supervised mixed exercise (5.1%), and participants with BMI ≤28.4 kg/m2 exercising during (5.2%) or post (9.5%) treatment. Conclusions: There are several systematic differences between cancer survivors completing and dropping out from exercise trials, possibly affecting the external validity of exercise effects.]]> Fri 08 Mar 2024 10:56:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33527 difference_in_effect = 0.13, 95%CI = 0.03;0.22) and PF (β_{difference_in_effect} = 0.10, 95%CI = 0.01;0.20) were significantly larger for supervised than unsupervised interventions. In conclusion, exercise, and particularly supervised exercise, effectively improves QoL and PF in patients with cancer with different demographic and clinical characteristics during and following treatment. Although effect sizes are small, there is consistent empirical evidence to support implementation of exercise as part of cancer care.]]> Fri 03 Dec 2021 10:34:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34907 interaction = -1.3 s, 95% confidence interval [CI] -2.6 to 0.0), whole-body lean mass (ß_interaction = 1194 g, 95% CI 234 to 2153) and ASM mass (ß_interaction = 562 g, 95% CI 49 to 1075), and approached significance for fat mass (ß_interaction = -1107 g, 95% CI -2346 to 132), with greater benefits for men previously on long-term ADT. At 6 months, the intervention effects on chair rise time -1.5 s (95% CI -2.5 to -0.5), whole-body lean mass 824 g (95% CI 8 to 1640), ASM mass 709 g (95% CI 260 to 1158), and fat mass -1377 g (95% CI -2156 to -598) were significant for men previously on long-term ADT, but not for men on short-term ADT. At 12 months, the intervention effects for men on long-term ADT remained significant for the chair rise, with improved performance (-2.0 s, 95% CI -3.0 to -1.0) and increased ASM (537 g, 95% CI 153 to 921). Time on ADT did not moderate the exercise effects on muscle strength, nor did time since ADT cessation moderate any intervention effects. Similarly, testosterone and baseline values of the outcome had negligible moderator effects. Conclusions: Men with PCa previously treated long-term with ADT respond more favourably to exercise in terms of lower body muscle performance and body composition (lean and fat mass, and ASM) than those with short-term ADT exposure. As a result, men who were formerly on long-term androgen suppression regimens should be especially prescribed exercise medicine interventions to alleviate residual treatment-related adverse effects.]]> Fri 01 Apr 2022 09:25:19 AEDT ]]>